Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

A Pulse on Innovation at the Heart of Cardiology 2025

MedscapeLIVE! is proud to present its annual Heart of Cardiology meeting, returning for its fifth year in Miami, Florida from January 24-26, 2025. Over 3 packed days at the Fontainebleau...

Medscape Education

- PMLiVE

WHO launches $1.5bn emergency appeal to tackle ongoing health crises

The appeal is aimed at providing urgent humanitarian assistance to more than 300 million people

- PMLiVE

Novo shares promising results for high-dose semaglutide in late-stage obesity study

The experimental dose is also being evaluated in adults with obesity and type 2 diabetes

- PMLiVE

Valneva shares positive phase 3 results for chikungunya vaccine in adolescents

The company has submitted label extension applications for Ixchiq in this age group

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

GSK’s Jemperli combination approved by EC for expanded endometrial cancer use

Approximately 417,000 new cases of the disease are reported globally every year

- PMLiVE

Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults

The company gained access to the drug through its $4.3bn acquisition of CymaBay

- PMLiVE

Innovative Trials appoints first Non-Executive Chair

John Watkinson is the new Non-Exec Chair as Innovative Trials targets significant business growth

Innovative Trials

IRA whitepaper_OPEN Health

The Potential Impact of the New Presidential Administration on the Future of the Inflation Reduction Act and Broader Healthcare Policy

Discover the key takeaways from OPEN Health’s latest whitepaper: "The Potential Impact of the New Presidential Administration on the Future of the Inflation Reduction Act and Broader Healthcare Policy."

OPEN Health

- PMLiVE

Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer

The combination therapy has been authorised for use in adults harbouring KRAS G12C mutations

- PMLiVE

ICR researchers uncover genes responsible for tumour progression in prostate cancer

The findings could pave the way for new treatment approaches that improve patient outcomes

- PMLiVE

AstraZeneca’s Calquence granted FDA approval in untreated mantle cell lymphoma

More than 27,500 people worldwide are affected by the rare form of non-Hodgkin lymphoma

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links